Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifampin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.96 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.96 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.96 |
| ▸ | MEN1 | O00255 | 2/20 | 0.96 |
| ▸ | GAA | P10253 | 2/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.96 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.96 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.96 |
| ▸ | ABCC2 | Q92887 | 2/20 | 0.96 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.96 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.96 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.96 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.96 |
| ▸ | SLCO1A2 | P46721 | 2/20 | 0.96 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.96 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifampin SCHEMBL4634484 | 1.00 | MAPT (0.96) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL14029509 | 0.98 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL1176203 | 0.98 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL14927261 | 0.98 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL14405975 | 0.98 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL19457678 | 0.98 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL23490 | 0.98 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL22432205 | 0.98 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL22517710 | 0.98 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E | |
| Rifampin SCHEMBL13230041 | 0.98 | MAPT (1.00) | MAPTNR1I2ABCB11ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3024445-B1 | ANTITUBERCULAR COMPOSITION COMPRISING RIFAMPICIN, ISONIAZID, ETHAMBUTOL AND PYRAZINAMIDE AND ITS PROCESS OF PREPARATION | SANOFI SA (FR) | 2019-01-09 | — | — | EP | disclosed |
| US-9814711-B2 | Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation | SANOFI (FR) | 2017-11-14 | — | — | US | disclosed |
| US-20160158226-A1 | ANTITUBERCULAR COMPOSITION COMPRISING RIFAMPICIN, ISONIAZID, ETHAMBUTOL AND PYRAZINAMIDE AND ITS PROCESS OF PREPARATION | SANOFI (FR) | 2016-06-09 | — | — | US | disclosed |
| US-20150110849-A1 | ANTIMICROBIAL ACCESSORY FOR AN IMPLANTABLE MEDICAL DEVICE | MEDTRONIC, INC. | 2015-04-23 | — | — | US | disclosed |
| CN-102365102-B | Antimicrobial accessory for an implantable medical device | MEDTRONIC INC | 2014-06-25 | — | — | CN | disclosed |
| CN-102365102-A | Antimicrobial accessory for an implantable medical device | MEDTRONIC INC | 2012-02-29 | — | — | CN | disclosed |
| CN-102341133-A | ANTIMICROBIAL ACCESSORY FOR IMPLANTABLE MEDICAL DEVICE | MEDTRONIC INC | 2012-02-01 | — | — | CN | disclosed |
| EP-2391396-A2 | ANTIMICROBIAL ACCESSORY FOR AN IMPLANTABLE MEDICAL DEVICE | Medtronic, Inc (US) | 2011-12-07 | — | — | EP | disclosed |
| CN-201959274-U | Capsule simultaneously containing rifampicin tablets, isoniazid tablets and ethambutol hydrochloride tablets | HEILONGJIANG FUHE HUAXING PHARMACEUTICAL GROUP CO LTD | 2011-09-07 | — | — | CN | disclosed |
| EP-2324041-A2 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | Targanta Therapeutics Corp. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100203100-A1 | ANTIMICROBIAL ACCESSORY FOR AN IMPLANTABLE MEDICAL DEVICE | MEDTRONIC, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| WO-2010088698-A2 | ANTIMICROBIAL ACCESSORY FOR AN IMPLANTABLE MEDICAL DEVICE | MEDTRONIC, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088697-A2 | ANTIMICROBIAL ACCESSORY FOR AN IMPLANTABLE MEDICAL DEVICE | MEDTRONIC, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010019511-A2 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100021390-A1 | Fluorescent Analogs Of The Islet Amyloid Polypeptide | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2010-01-28 | — | — | US | disclosed |
| WO-2002087547-A1 | AN IMPROVED PROCESS FOR PREPARATION OF FOUR-DRUG ANTI-TUBERCULAR FIXED DOSE COMBINATION | LUPIN LIMITED (IN) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021390-A1 | Fluorescent Analogs Of The Islet Amyloid Polypeptide | IAPP, APP, AMY2A | MAPT 999/4885NR1I2 4384/4885ABCB11 3410/4885 |
| US-20160158226-A1 | ANTITUBERCULAR COMPOSITION COMPRISING RIFAMPICIN, ISONIAZID, ETHAMBUTOL AND PYRAZINAMIDE AND ITS PROCESS OF PREPARATION | EXOSC9, SRI, CYP3A5 | MAPT 145/4885NR1I2 1349/4885ABCB11 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.